Status:
UNKNOWN
Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
Lead Sponsor:
Huashan Hospital
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by persistent airflow limitation and associated with an accelerated decline in lung function, impaired quality of life, ho...
Eligibility Criteria
Inclusion
- Clinical diagnosis of group A or group B stable COPD. Must be able to inhale Formoterol or Tiotropium.
Exclusion
- Asthma. Cystic fibrosis. Bronchiectasis. Lung cancer. Glaucoma. Tachyarrhythmia or other serious heart diseases. Prostatic hyperplasia.
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03258749
Start Date
November 1 2017
End Date
October 31 2018
Last Update
October 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan hospital,Fudan university
Shanghai, Shanghai Municipality, China, 200040